iSBTc 23rd Annual Meeting
October 31 - November 2, 2008
Westin Gaslamp Quarter Hotel
San Diego, CA
The iSBTc Annual Meeting facilitated exchange of the most cutting edge preclinical and clinical data on the use of biological therapies in cancer between basic scientists and clinicians from academic, regulatory and industrial venues. This meeting provided education on the latest advances and allowed investigators to share and build on their data, ultimately leading to better patient outcomes in cancer.
- Adoptive Transfer
- Cancer Stem Cells and the Host Response
- Cancer and Inflammation +
- Co-Stimulation / Immunoregulation *
- Dendritic Cells *
- Endpoints, Response Criteria for Clinical Trial Design
- Enhancing Cancer Vaccines
- Infectious Agent Vectors *
- Innate Immunity to Tumors
- New Agents *
- TH-17, Cytokines and T Cell Subsets
- Trafficking and in vivo Imaging *
- Tumor Escape / Tumor Microenvironment
- Tumor Targeting Monoclonal Antibodies
* Poster only category
+ Abstract selected for oral presentation in this category were presented at the Workshop.
Basic and clinical investigators involved in cancer research comprising members of academic, pharmaceutical, and regulatory agencies including basic scientists, clinicians, graduate students and post-doctoral fellows, as well as allied health professionals.
- Promote scientific exchange of most recent advances and data in the biological treatment of cancer, as well as advances in basic cancer biology with relevance for anti-tumor immunity
- Promote the generation of new ideas incorporating these advances and explore their potential for impact on treatment outcomes
- Discuss the latest clinical developments regarding application of biologic approaches and establish dialogue between academia, government and industry regarding implications as well as future directions
- Educate and provide perspective to the audience on the broad range of scientific developments in cancer and biological approaches to therapy
- Discuss therapeutic approaches to cancer immunotherapy including: cancer vaccines, adoptive T cell transfer, monoclonal antibodies, gene therapy, and use of cytotoxic or molecular targeting agents in combination with immune therapy.
- Discuss current approaches to immunological monitoring
- Discuss current regulatory guidelines and how they impact clinical trials as well as resource availability
Expected Learner Outcomes
Upon completion of this meeting, participants will be able to:
- Summarize the most recent advances in cancer biology, how they intersect with the immune system, and how these considerations are relevant for the biologic therapy of cancer . These include but are not limited to: cancer stem cells, inflammation and cancer, cancer dormancy, and angiogenesis.
- Discuss the latest information about clinical/translational work in cancer immunotherapy.
- Establish how to solidify collaborations among the various members of academia, industry, and clinical practices to initiate clinical evaluation of these advances in more efficient trials.
- Compare options available in trial design including immune monitoring techniques and compliance with regulatory guidelines.
- Locate resources available through government agencies (funds, data-bases, tissue banks, etc.) that can facilitate translational research.
Thomas A. Davis, MD
Celldex Therapeutics, Inc.
Thomas F. Gajewski, MD, PhD
University of Chicago
William J. Murphy, PhD
University of California Davis, School of Medicine
Hideaki Tahara, MD, PhD
University of Tokyo